Table I.
c-Met expression in ovarian cancer samples and available clinical data.
| Sample | Diagnosis | Score | CR vs. IR | Debulking | Age (years) | Stage | CA125 |
|---|---|---|---|---|---|---|---|
| 1 | Focal adenocarcinoma | 6 | CR | O | 57 | IIIC | 541 |
| 2 | Papillary serous adenocarcinoma | 1 | CR | O | 84 | IIIC | 7350 |
| 3 | Adenocarcinoma | 2 | CR | O | 53 | IIIC | |
| 4 | Papillary serous adenocarcinoma | 4 | CR | O | 61 | IIIC | |
| 5 | Papillary serous adenocarcinoma | 6 | CR | O | 57 | IIIC | |
| 6 | Papillary serous adenocarcinoma | 1 | CR | O | 55 | IV | |
| 7 | Papillary serous adenocarcinoma | 2 | CR | O | 49 | IIIC | 305 |
| 8 | Papillary serous adenocarcinoma | 1 | CR | O | 65 | IIIC | |
| 9 | Papillary serous adenocarcinoma | 4 | CR | O | 60 | IIIC | 925 |
| 10 | Papillary serous adenocarcinoma | 2 | CR | O | 51 | IIIB | |
| 11 | Papillary serous adenocarcinoma | 4 | CR | O | 56 | IIIC | 316 |
| 12 | Papillary serous adenocarcinoma | 2 | CR | O | 66 | IIIC | 224 |
| 13 | Papillary serous adenocarcinoma | 2 | CR | S | 56 | IIIC | |
| 14 | Papillary serous adenocarcinoma | 4 | CR | O | 73 | IIIC | |
| 15 | Papillary serous adenocarcinoma | 1 | CR | O | 62 | IIIC | 1717 |
| 16 | Papillary serous adenocarcinoma | 2 | CR | O | 78 | IIIC | |
| 17 | Papillary serous adenocarcinoma | 6 | CR | O | 43 | IIIC | 64 |
| 18 | Papillary serous adenocarcinoma | 1 | CR | O | 45 | IIIC | |
| 19 | Papillary serous adenocarcinoma | 1 | CR | S | 74 | IIIC | 1800 |
| 20 | Papillary serous adenocarcinoma | 2 | CR | O | 76 | IIIC | |
| 21 | Papillary serous adenocarcinoma | 2 | IR | S | 79 | IV | |
| 22 | Papillary serous adenocarcinoma | 2 | IR | S | 71 | IV | 1636 |
| 23 | Papillary serous adenocarcinoma | 2 | CR | O | 56 | IIIC | |
| 24 | Papillary serous adenocarcinoma | 1 | CR | O | 81 | IIIC | |
| 25 | Papillary serous adenocarcinoma | 2 | CR | O | 56 | IIIC | 260 |
| 26 | papillary serous adenocarcinoma | 3 | CR | O | 35 | IV | 47 |
| 27 | Papillary serous adenocarcinoma | 2 | CR | O | 53 | IIIA | |
| 28 | Papillary serous adenocarcinoma | 1 | CR | S | 77 | IV | >600 |
| 29 | Papillary serous adenocarcinoma | 2 | CR | O | 65 | IIIC | 1118 |
| 30 | Papillary serous adenocarcinoma | 1 | CR | S | 47 | IIIC | 712 |
| 31 | Papillary serous adenocarcinoma | 2 | CR | S | 76 | IIIC | 1848 |
| 32 | Papillary serous adenocarcinoma | 2 | CR | O | 70 | IIIC | |
| 33 | Papillary serous adenocarcinoma | 3 | CR | S | 57 | IIIC | 266 |
| 34 | Adenocarcinoma metastatic | 2 | CR | O | 57 | IIIC | 175 |
| 35 | Papillary serous adenocarcinoma | 1 | CR | O | 65 | IV | 404 |
| 36 | Papillary serous adenocarcinoma | 2 | CR | O | 76 | IV | |
| 37 | Papillary serous adenocarcinoma | 1 | CR | O | 66 | IIIC | |
| 38 | Papillary serous adenocarcinoma | 1 | CR | O | 68 | IIIC | |
| 39 | Papillary serous adenocarcinoma | 3 | IR | O | 73 | IIIC | |
| 40 | Papillary serous adenocarcinoma | 2 | CR | O | 63 | IV | |
| 41 | Papillary serous adenocarcinoma | 2 | IR | S | 63 | IIIC | |
| 42 | Papillary serous adenocarcinoma | 2 | IR | O | 47 | IIIC | |
| 43 | Papillary serous adenocarcinoma | 2 | CR | O | 42 | IIIC | 110 |
| 44 | Papillary serous adenocarcinoma | 1 | CR | O | 74 | IIIC | 4557 |
| 45 | Papillary serous adenocarcinoma | 2 | CR | S | 64 | IIIC | |
| 46 | Papillary serous adenocarcinoma | 2 | IR | S | 64 | IIIC | 456 |
| 47 | Papillary serous adenocarcinoma | 1 | IR | O | 71 | IIIC | |
| 48 | Papillary serous adenocarcinoma | 6 | IR | O | 69 | IIIC | |
| 49 | Papillary serous adenocarcinoma | 3 | CR | O | 49 | IIIC | |
| 50 | Papillary serous adenocarcinoma | 2 | CR | O | 62 | IV | |
| 51 | Papillary serous adenocarcinoma | 2 | IR | ||||
| 52 | Focal adenocarcinoma | 3 | CR | S | 88 | IIIC | |
| 53 | Serous adenocarcinoma | 1 | IR | O | 74 | IIIC | 101 |
| 54 | Papillary serous adenocarcinoma | 2 | IR | O | 71 | IIIC | |
| 55 | Papillary serous adenocarcinoma | 4 | IR | O | 69 | IIIC | 1606 |
| 56 | Papillary serous adenocarcinoma | 1 | IR | O | 52 | IIIC | |
| 57 | Papillary serous adenocarcinoma | 2 | CR | O | 67 | IIIC | |
| 58 | Papillary serous adenocarcinoma | 1 | CR | O | 66 | IIIC | 824 |
| 59 | Papillary Serous adenocarcinoma | 2 | IR | O | 52 | IIIC | |
| 60 | Papillary serous adenocarcinoma | 1 | CR | S | 73 | IIIC | 2354 |
| 61 | Papillary serous adenocarcinoma | 0 | CR | O | 75 | IIIC | |
| 62 | Papillary serous adenocarcinoma | 2 | IR | O | 65 | IIIC | |
| 63 | Focal cellular atypia | n/a | CR | O | 74 | IIIC | |
| 64 | Papillary serous adenocarcinoma | 2 | IR | O | 79 | IIIC | 417 |
| 65 | Papillary serous adenocarcinoma | 1 | CR | O | 73 | IIIC | 180 |
| 66 | Papillary serous adenocarcinoma | 2 | IR | O | 53 | IV | 96 |
| 67 | Papillary serous adenocarcinoma | 1 | CR | O | 60 | IIIC | |
| 68 | Papillary serous adenocarcinoma | 2 | CR | ||||
| 69 | Papillary serous adenocarcinoma | 2 | IR | S | 53 | IIIC | |
| 70 | Papillary serous adenocarcinoma | 1 | IR | O | 41 | IIIC | 2800 |
| 71 | Papillary serous adenocarcinoma | 1 | CR | O | 80 | IIIC | |
| 72 | Papillary serous adenocarcinoma | 2 | CR | O | 42 | IIIA | |
| 73 | Papillary serous adenocarcinoma | 2 | IR | S | 66 | IIIC | 90 |
| 74 | Papillary serous adenocarcinoma | 1 | CR | S | 60 | IIIC | 750 |
| 75 | Papillary serous adenocarcinoma | 4 | CR | O | 77 | IIIC | 9814 |
| 76 | Papillary serous adenocarcinoma | 0 | CR | O | 72 | III | |
| 77 | Papillary serous adenocarcinoma | 1 | IR | O | 66 | IIIC | |
| 78 | Papillary serous adenocarcinoma | 0 | CR | O | 54 | III | |
| 79 | Papillary serous adenocarcinoma | 3 | CR | O | 38 | IIIC |
The c-Met expression score was determined by intensity × cellularity, where intensity was graded as 1, weak; 2, moderate; or 3, strong, and cellularity was graded as 1 when ≤33%, 2 when 34–65%, or 3 when ≥66%. CR, complete response; IR, incomplete response to primary therapy.